The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective

被引:54
|
作者
Garbaccio, Robert M. [1 ]
Parmee, Emma R. [1 ]
机构
[1] Merck Res Labs, Global Chem, Mailstop 14-2,740 Sumneytown Pike, West Point, PA 19486 USA
来源
CELL CHEMICAL BIOLOGY | 2016年 / 23卷 / 01期
关键词
SMALL-MOLECULE INHIBITORS; PEPTIDASE-IV INHIBITOR; RECEPTOR; TARGET; ANTAGONIST; POTENT; CELLS; AKT; REPLICATION; MK-0657;
D O I
10.1016/j.chembiol.2015.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemical probes represent an important component of both academic and pharmaceutical drug discovery research. As a complement to prior reviews that have defined this scientific field, we aim to provide an industry perspective on the value of having high-quality chemical probes throughout the course of preclinical research. By studying examples from the internal Merck pipeline, we recognize that these probes require significant collaborative investment to realize their potential impact in clarifying the tractability and translation of a given therapeutic target. This perspective concludes with recommendations for chemical probe discovery aimed toward maximizing their potential to identify targets that result in the successful delivery of novel therapeutics.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [21] Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry
    Caille, Seb
    Cui, Sheng
    Faul, Margaret M.
    Mennen, Steven M.
    Tedrow, Jason S.
    Walker, Shawn D.
    JOURNAL OF ORGANIC CHEMISTRY, 2019, 84 (08): : 4583 - 4603
  • [22] Macromolecular crystallography from an industrial perspective - the impact of synchrotron radiation on structure-based drug discovery
    Kack, H.
    Sjogren, T.
    JOURNAL OF SYNCHROTRON RADIATION, 2025, 32 : 294 - 303
  • [23] Subtleties in GPCR drug discovery: a medicinal chemistry perspective
    Fujioka, Masahiko
    Omori, Naoki
    DRUG DISCOVERY TODAY, 2012, 17 (19-20) : 1133 - 1138
  • [24] Rethinking 'academic' drug discovery: the Manchester Institute perspective
    Jordan, Allan M.
    Waddell, Ian D.
    Ogilvie, Donald J.
    DRUG DISCOVERY TODAY, 2015, 20 (05) : 525 - 535
  • [25] A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders
    Gastfriend, David R.
    ADDICTION REVIEWS, 2014, 1327 : 112 - 130
  • [26] Twenty years on: the impact of fragments on drug discovery
    Erlanson, Daniel A.
    Fesik, Stephen W.
    Hubbard, Roderick E.
    Jahnke, Wolfgang
    Jhoti, Harren
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (09) : 605 - 619
  • [27] Biophysics in drug discovery: impact, challenges and opportunities
    Renaud, Jean-Paul
    Chung, Chun-wa
    Danielson, U. Helena
    Egner, Ursula
    Hennig, Michael
    Hubbard, Roderick E.
    Nar, Herbert
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (10) : 679 - 698
  • [28] Application of chemical biology in target identification and drug discovery
    Zhu, Yue
    Xiao, Ting
    Lei, Saifei
    Zhou, Fulai
    Wang, Ming-Wei
    ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (09) : 1642 - 1650
  • [29] Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody- drug conjugate development
    Ma, Qi
    Durga, Puro
    Wang, Frederick X. C.
    Yao, Hang-Ping
    Wang, Ming-Hai
    DRUG DISCOVERY TODAY, 2024, 29 (08)
  • [30] Diversity-Oriented Synthetic Strategies Applied to Cancer Chemical Biology and Drug Discovery
    Collins, Ian
    Jones, Alan M.
    MOLECULES, 2014, 19 (11): : 17221 - 17255